Efficacy of mepolizumab in patients with COPD & type 2 inflammation: Pooled Phase III trial results

Pneumologie 2026

View at publisher
Authors: Claus Franz Vogelmeier, Alberto Papi, Mona Bafadhel, Gilles Devouassoux, Mohit Bhutani, M Han, Bhabita Mayer, Joel Schamroth, Steven Gould, Frank C. Sciurba
DOI: 10.1055/s-0046-1816502
Cited by: 0

Abstract

Background: MATINEE (NCT02105948) enrolled patients with all COPD subtypes and blood eosinophil count (BEC)≥300 cells/µL. METREX/METREO (NCT02105961/04133909) enrolled patients with BEC≥300 as well as

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Asthma and respiratory diseases Cystic Fibrosis Research Advances

Publication details

Journal / source
Pneumologie
Volume
80
Publication date
1 March 2026
Language
EN